checkAd

     117  0 Kommentare Interim Report January-September 2023

    GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2023 (July 1 - September 30) • Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent in SEK and …

    GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)

    Third quarter 2023 (July 1 - September 30)
    • Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent in SEK and 42 percent in local currencies. • Organic growth accounted for 37 percent and acquired growth for 5 percent.
    • All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 23 percent, Abdominal disposables 100 percent and Services 68 percent.
    • The gross margin for disposables increased to 80 percent (79). The total gross margin was 73 percent (72).
    • Operating income (EBIT) amounted to SEK 5.3 million (-4.7).
    • Adjusted EBIT amounted to SEK 14.4 million (-0.7).
    • Operating income before depreciation and amortization (EBITDA) amounted to SEK 18.9 million (5.9), corresponding to an EBITDA margin of 13 percent (6).
    • Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 28.0 million (9.9), corresponding to an adjusted EBITDA margin of 19 percent (10).
    • Net profit amounted to SEK 2.3 million (5.4).
    • Earnings per share amounted to SEK 0.08 (0.18).
    • Cash flow from operating activities increased to SEK 24.8 million (17.0), primarily due to strong operating income before depreciation and amortization. Total cash flow amounted to SEK 424.4 million (-18.4), mainly comprising net proceeds from a new issue of SEK 440 million, and investments in R&D projects totaling SEK -21.5 million (-27.9).

    Significant events during the quarter
    • A directed share issue raised SEK 440 million before transaction costs and was completed with no discount
    • US FDA grants XVIVO approval to include DCD hearts in IDE Clinical Trial
    • XVIVO's heart preservation technology was used in a second successful xenotransplant (heart from pig to human)
    • Strategic collaboration with MTJ Aviation aimed at strengthening XVIVO's service for organ retrieval in the US
    • Further patient inclusion in the PrimECC study concluded Study data will be analyzed and strategic opportunities evaluated

    Lesen Sie auch

    The period 2023 (January 1 - September 30)
    • Net sales amounted to SEK 441.8 million (283.8), corresponding to an increase of 56 percent in SEK and 45 percent in local currencies.
    • Organic growth accounted for 39 percent and acquired growth for 6 percent.
    • All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 34 percent, Abdominal disposables 71 percent and Services 75 percent.
    • Gross margin for disposables increased to 80 percent (79). The total gross margin was 74 percent (71).

    Seite 1 von 3




    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Interim Report January-September 2023 GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2023 (July 1 - September 30) • Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent in SEK and …